Clinical trials on Follicular Lymphoma

Follicular Lymphoma: An Overview

Follicular Lymphoma (FL) is a type of non-Hodgkin lymphoma that is generally considered indolent, meaning it grows slowly. It originates from the B lymphocytes (B cells), which are an integral part of the body’s immune system. Characterized by the formation of tumor cells in the lymph nodes, it typically presents in a follicular pattern when observed under a microscope, hence its name. FL is the second most common subtype of non-Hodgkin lymphomas, accounting for about 20-30% of all cases. It predominantly affects adults, with a median age of diagnosis around 60 years, and has a slight predilection for females.

The clinical presentation of Follicular Lymphoma can vary widely among patients. Some may experience no symptoms at all and are diagnosed incidentally during routine examinations, while others may present with swollen lymph nodes, fatigue, weight loss, or night sweats. The disease is often diagnosed at a relatively advanced stage, primarily because it progresses so slowly that symptoms take a long time to develop. Despite its indolent nature, FL is challenging to cure and has a relapsing-remitting course. Treatment strategies may include watchful waiting for asymptomatic patients, radiation therapy for localized disease, and systemic therapies such as chemotherapy, immunotherapy, or a combination thereof for advanced stages.

Advancements in the understanding of Follicular Lymphoma have led to the development of targeted therapies and personalized medicine approaches, significantly improving the quality of life and survival rates for many patients. However, the heterogeneity of the disease and its tendency to transform into a more aggressive form of lymphoma in a subset of patients underscore the importance of ongoing research and clinical trials to uncover more effective treatments and potential cures.